Thrombosis in neonates and children

Yıl 2009, Cilt: 14 Sayı: 2, 36 - 45, 14.01.2013

Tulika Seth

Öz

Abstract. The incidence of thrombosis is lower in children than in adults, however thrombosis related pediatric morbidity and mortality are significant. The incidence of thrombosis is maximum in neonates and during adolescence. The hemostatic system in the newborn differs from children and adults. Children till 6 months of age have lower levels of the vitamin-K–dependent coagulation factors II, IX, and X, compared to adults. Levels of thrombin inhibitors, such as antithrombin and heparin cofactor II, are similarly low at birth. Levels of protein C and S are low at birth. Protein S levels approach adult values by the age of 3-6 months, but protein C levels remain low even into childhood. Furthermore, plasminogen levels are low in newborns and infants. Thrombin generation is decreased (probably because of low prothrombin levels) and delayed in newborns compared with adults. There is a second peak of thrombosis during adolescence with more adult like risk factors

In this article we will review the literature for pertinent clinical and management issues of experts in the field of neonatal and pediatric thrombosis. The material is presented in a manner that is to relevant to clinical practice.

 

Key words:  Adolescence thrompbophilia, pediatric anticoagulation, newborn hemostatic system

Anahtar Kelimeler

-

Kaynakça

• Williams MD, Chalmers EA, Gibson BES. The investigation and management of neonatal haemostasis and thrombosis. Guideline. Haemostasis and Thrombosis Task the Royal College of Paediatrics and Child Health, the British Association for Paediatric Medicine and the Paediatric Haematology Forum. British Journal of Haematology 2002; 119: 295-309.
• Beardsley DS. Venous thromboembolism in the neonatal period. Semin Perinatol 2007; 31: 250- 253.
• Monagle P, Chalmers E, Chan A, et al. Michelson AD. Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 2008; 133: 887-968.
• Albisetti M, Chan AKC, Mahoney, Donald H , Kim MS.UpToDate 2008. http://www.uptodate.com/home/clinicians/specia lties/hematology.html
• Edstrom CS, Christensen D. Evaluation and treatment of thrombosis in the neonatal intensive care unit. Clin Perinatol 2000; 27: 623-641.
• Deally C, Hamcock BJ, Giddins N, et al. Primary anti phospholipid syndrome: A cause of Catastrophic shunt thrombosis in the newborn. J Cardiovasc Surg 1999; 40: 261.
• de Klerk OL, de Vries TW, Sinnige LGF. An unusual cause of neonatal seizures in a new born infant. Pediatrics 1997; 100: E8.
• Manco-Johnson MJ. Diagosis and management of thromboses in the perinatal period. Semin perinatol 1990; 14: 393.
• Roy M, Turner-Gomes S, Gill G, Way C, Mernagh J, Schmidt B. Accuracy of Doppler echocardiography for the diagnosis of thrombosis associated with umbilical venous catheters. J Pediatr. 2002; 140(1):131-134.
• Vailas GN, Brouillette RT, Scott JP, et al. Neonatal aortic thrombosis: recent experience. J Pediatr. 1986; 109(1): 101-108.
• Mcdonald MM, Hathaway WE. Anticoagulant therapy by continuous heparinization in newborn and older infants. J Pediatr 1982; 101: 451-457.
• Manco-Johnson MJ. Diagnosis and management of thromboses in the perinatal period. Semin perinatol 1990; 14: 393.
• Schmidt B, Buchanan MR, Ofosu F, et al. Anti- Thrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Thromb Hemostas 1988; 60: 289.
• Schmidt B, Ofosu FA, Mitchell L, et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25(4): 405-408.
• Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35(1): 78-83.
• Schmidt B, Mitchell L, Ofosu F, et al. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988; 112: 641-643.
• Massicotte P, Adams M, Marzinotto V, et al. Low- molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996; 128: 313-318.
• Massicotte P, Julian JA, Gent M, et al. REVIVE Study Group. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109: 85-92.
• Andrew M, Michelson AD, Bovill E, et al. Guidelines for anti-thrombotic therapy in paediatric patients. J Pediatr 1998; 132: 575.
• Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: A prospective cohort study. J Pediatr 2000; 136: 639-45.Blood 1999; 94: 3007-3014.
• Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139: 682-688.
• Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94: 3007.
• Dreyfus M, Masterson M, David M, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost. 1995; 21: 371-381.
• Monagle P, Andrew M, Halton J, et al. Massicotte MP. Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost. 1998; 79: 756-761.
• David, M, Manco-Johnson, M, Andrew, M. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the Subcommittee on Perinatal Haemostasis of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 791.
• Male C, Chait P, Ginsberg J, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Thromb Haemost 2002; 87: 593.
• Kroencke, TJ, Taupitz M, Arnold R, et al. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. Chest 2001; 120: 1570.
• Revel-Vilk, S, Sharathkumar, A, Massicotte, P, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. J Thromb Haemost 2004; 2: 42.
• Ignjatovic, V, Summerhayes, R, Than, J, et al. Therapeutic range for unfractionated heparin therapy: age-related differences in resp.onse in children. J Thromb Haemost 2006; 4: 2280
• Newall, F, Barnes, C, Savoia, H, et al. Warfarin therapy in children who require long-term total parenteral nutrition. Pediatrics 2003; 112: e386.
• Terrill, KR, Lemons, RS, Goldsby, RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr Hematol Oncol 2003; 25:864.
• Albisetti, M. Thrombolytic therapy in children. Thromb Res 2006; 118: 95.
• Choi, M, Massicotte, MP, Marzinotto, V, et al. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 2001; 139: 152.